Kisspeptin: upstream of the whole hormonal cascade

The short answer

• Kisspeptin is a hypothalamic neuropeptide that acts one step above GnRH. It binds KISS1R on GnRH neurons, which release GnRH, which drives pituitary LH and FSH.
• Evidence tier: Human trials for reproductive-hormone physiology and for triggering oocyte maturation in IVF (phase 2). Early human data for hypothalamic amenorrhea, male hypogonadism and low sexual desire.
• It is not approved anywhere, for anything, as of September 2026.
• The single strongest human evidence in the field is genetic, not pharmacological: people born with inactivating mutations in the receptor gene fail to go through puberty.
• Human dosing in trials is by body weight and mostly intravenous. Flat microgram subcutaneous doses circulating online have no trial behind them.
• Two facts make the “more, more often” instinct actively wrong here. The kisspeptin-10 dose response is non-monotonic, and frequent dosing causes tachyphylaxis within days.
• Kisspeptin-10 sits in FDA 503A Category 2, bulk substances that raise significant safety risks, on the list updated 14 May 2026. It is prohibited in males at all times under WADA S2.2.1 on the 2026 list.

What it actually is

Kisspeptin is the product of the KISS1 gene. Two forms matter. Kisspeptin-54, also called metastin, is the full-length 54-amino-acid circulating form. Kisspeptin-10 is the C-terminal decapeptide, the short business end that still binds the receptor. Both are RF-amide peptides sharing the same C-terminal motif, which is the receptor-binding region.

The receptor is KISS1R, formerly called GPR54. It sits on GnRH neurons in the hypothalamus. Kisspeptin neurons live in the arcuate nucleus and preoptic area, co-express neurokinin B and dynorphin (hence “KNDy neurons”), and integrate sex-steroid feedback along with metabolic and stress signals.

So the chain runs: kisspeptin neurons, then GnRH neurons, then pituitary LH and FSH, then the gonads. Kisspeptin is a releasing-factor releasing factor. If you want the layer below it, TRT versus peptide therapy covers where exogenous hormones interrupt the same axis.

Why the genetics matter more than the trials

The most convincing evidence that this pathway is essential came from two 2003 papers, not from a drug study. Inactivating mutations in GPR54/KISS1R cause normosmic congenital hypogonadotropic hypogonadism with absent puberty (Seminara 2003; de Roux 2003). Remove the receptor and puberty does not happen.

That is a much stronger claim than anything a small dosing study can produce, and it is the reason the field exists. It also sets a hard limit on what kisspeptin can do as a drug: because it works through endogenous GnRH, it needs an intact hypothalamus and a responsive pituitary. It cannot rescue pituitary failure. In a head-to-head intravenous study in healthy men, LH and FSH rose about 3-fold higher with GnRH than with kisspeptin-10, and about 2-fold higher than with kisspeptin-54, because GnRH hits the pituitary directly (Jayasena 2015).

What the human studies established

Dozens of small, carefully controlled human studies define what a kisspeptin dose does to LH, FSH, testosterone and estradiol. Most come from one group at Imperial College London, with additional work in Boston and Edinburgh.

A few representative findings:

• Kisspeptin-54 infused intravenously at 4 pmol/kg/min over 90 minutes in healthy men raised mean LH from 4.2 to 10.8 IU/L (Dhillo 2005).
• The response in women is dramatically cycle-dependent. Mean LH rose 20.6 IU/L in the preovulatory phase against 0.12 IU/L in the follicular phase (Dhillo 2007). A dose is not a dose without a cycle phase attached.
• Kisspeptin-54’s plasma half-life after intravenous infusion in men is 27.6 minutes (Dhillo 2005). No validated human half-life exists for kisspeptin-10.
• Intranasal delivery works. In a 2025 first-in-human study, kisspeptin-54 up to 12.8 nmol/kg raised LH by 4.4 IU/L in healthy men, 1.4 IU/L in healthy women and 4.4 IU/L in hypothalamic amenorrhea, with no adverse events reported (Mills 2025).

The most developed therapeutic application is as an IVF trigger. Kisspeptin-54 reliably induces an LH surge lasting roughly 12 to 14 hours. In women at high risk of ovarian hyperstimulation syndrome, it matured oocytes in 95% of participants with live birth rates per transfer of 45%, and no moderate, severe or critical OHSS occurred in that cohort (Abbara 2015). A second dose at 10 hours raised the proportion of women reaching the oocyte-yield target from 45% to 71% (Abbara 2017).

That is real, and it is still phase 2 at a single centre. Kisspeptin has never been compared head-to-head with the established GnRH-agonist trigger in an adequately powered trial, so “lower OHSS risk than hCG” remains plausible but unproven.

The desire studies, read carefully

Kisspeptin modulates limbic and sexual-processing circuits in humans on functional MRI (Comninos 2017). That led to two randomised crossover trials in people with hypoactive sexual desire disorder, one in women and one in men, each with roughly 32 completers (Thurston 2022; Mills 2023).

The endpoints were brain imaging and, in the male trial, penile tumescence. They were not validated desire or distress instruments measured over time, and they were not clinical outcome trials. They justify further research; they do not justify treatment. For context, the two approved pharmacological options for HSDD produce small average benefits with meaningful side effects, which is why diagnosis and modifiable contributors matter more than the choice of molecule. The glossary unpacks the trial-phase vocabulary if it is unfamiliar.

Where the community protocols go wrong

Kisspeptin-10 is sold by research-chemical vendors and used off-label for “testosterone support” or libido. This article will not reproduce those regimens, and there are specific pharmacological reasons they do not work as advertised.

The dosing units do not match the evidence. Nearly all human data are weight-based and intravenous. Flat subcutaneous microgram figures have no trial behind them at all.

More is not better, literally. In healthy men, a 1 mcg/kg intravenous bolus of kisspeptin-10 maximally stimulated LH, raising it from 4.1 to 12.4 IU/L at 30 minutes. A 3 mcg/kg dose produced a smaller response (George 2011). The dose response is non-monotonic, so the standard community habit of titrating upward when nothing happens produces less effect, not more.

Frequent dosing shuts the response down. Kisspeptin-54 given twice daily for two weeks caused tachyphylaxis of the LH and FSH response (Jayasena 2009). Interestingly, pituitary responsiveness to GnRH itself was preserved, meaning the desensitisation happens upstream. Twice-weekly dosing caused only partial desensitisation and still raised reproductive hormones at eight weeks (Jayasena 2010). Any daily or twice-daily protocol is working directly against the pharmacology.

The male evidence is five patients. The proof-of-concept study in men with type 2 diabetes and mild biochemical hypogonadism enrolled five people (George 2013). Against that, hCG acts directly on Leydig cells and has decades of use, and the SERMs enclomiphene and clomiphene have phase 2 data for raising testosterone while preserving sperm counts. There is no basis for choosing kisspeptin over those in practice.

Safety, honestly stated

Across the published human studies kisspeptin has been strikingly well tolerated. Trials repeatedly report no adverse events attributable to the peptide, including the intranasal study and both HSDD trials. No serious drug-related adverse events have been published in the IVF trials.

That tolerability is real but narrow. It describes single or short-course weight-based doses in monitored research settings. What does not exist: any repeated-dosing safety study of meaningful duration in men, any carcinogenicity or fertility data, any multi-year human exposure data. Kisspeptin also has insulin-secretion effects under study, so the metabolic consequences of chronic exposure are uncharacterised.

The mechanism-based cautions are straightforward. It should not be used where an LH surge is unwanted, or for unmonitored ovarian stimulation, where uncontrolled ovulation induction and multiple pregnancy are real risks.

The regulatory picture as of September 2026: no DIN in Canada, and kisspeptin is named explicitly in Health Canada advisories on seized unauthorized injectable peptides from April and August 2025. Kisspeptin-10 is in FDA 503A Category 2, which means the FDA has identified significant safety risks, so no US compounding pharmacy should be supplying it as a bulk substance. Health Canada’s 9 April 2026 advisory is clear that a “research use only” label confers no legal status of its own. For athletes, kisspeptin and its agonist analogues are prohibited in males at all times under WADA S2.2.1.

The bottom line

Kisspeptin has some of the cleanest human mechanism data in the peptide world and no approved use anywhere. Its genuine near-term roles are as a diagnostic probe of whether a patient’s GnRH neurons work and as a phase 2 IVF trigger for women at high OHSS risk. The way it is sold and used online contradicts its own pharmacology on two counts, dose response and dosing frequency, which is an unusual failure mode worth understanding on its own terms. See starting peptide research for how to read this kind of evidence gap in general.

Education only. This page is educational. Most compounds referenced are not approved for human use, and a “research use only” label carries no legal status of its own. Nothing here constitutes medical advice, diagnosis, or treatment.

Sources

• Seminara SB, et al. The GPR54 gene as a regulator of puberty. N Engl J Med, 2003.
• de Roux N, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A, 2003.
• Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab, 2005.
• George JT, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab, 2011.
• Jayasena CN, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab, 2009.
• Jayasena CN, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod, 2015.
• Abbara A, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab, 2015.
• FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, categories list updated 14 May 2026; WADA 2026 Prohibited List, section S2.2.1; Health Canada advisories on unauthorized injectable peptides, April and August 2025.